Advertisement

Topics

ImmunoGen Company Profile

07:12 EDT 23rd September 2017 | BioPortfolio

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. The small-molecule drugs are highly potent cell-killing (cytotoxic) agents, while the monoclonal antibodies identify and bind to tumor cells. An important characteristic of TAPs is that they remain inactive and nontoxic until they bind to the surface of a tumor cell, after which their full cytotoxicity is restored.

Location

128 Sidney Street
Cambridge
MA
02139
United States of America

Contact

Phone: (617) 995-2500
Fax: 617-995-2510


News Articles [78 Associated News Articles listed on BioPortfolio]

Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More

ImmunoGen has yet to bring one of its own antibody cancer drugs to market, but the Waltham, MA, company has had some success with its pharma partners. On Tuesday it added Jazz Pharmaceuticals to the m...

ImmunoGen and Sanofi amend license deals

ImmunoGen and an affiliate of Sanofi have amended their license agreements to cover all compounds developed by the latter using ImmunoGen’s technology.

ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4. ...

For InvestorsImmunoGen, Inc.Sarah Kiely, 781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen, Inc.Courtney O’Konek, 781-895-0158courtney.okonek@immunogen.comorFTI Consulting, Inc...

-$0.40 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter

Equities analysts expect ImmunoGen, Inc. to report earnings of per share for the current quarter, according to Zacks . Four analysts have made estimates for ImmunoGen's earnings.

ImmunoGen and Sanofi Amend License Agreements Covering All Sanofi Compounds Using ImmunoGen’s Technology

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Comp...

ImmunoGen grants Sanofi exclusive, fully-paid licenses to selected development compounds

  ImmunoGen has announced that the Company and an affiliate of Sanofi have amended their license agreements covering all compounds in development by Sanofi using ImmunoGen’s technology. Un...

ImmunoGen sells off ADC to Debiopharm

Debiopharm moves into antibody-drug conjugates as it buys ImmunoGen’s IMGN529 in a $55 million deal.

ImmunoGen grants Jazz rights to antibody-drug conjugate programs

Jazz Pharmaceuticals was granted an exclusive option to develop and commercialize ImmunoGen's IMGN779, IMGN632 and a third un -More- 

Drugs and Medications [0 Results]

None

PubMed Articles [28 Associated PubMed Articles listed on BioPortfolio]

Doses of Immunogen Contribute to Specificity Spectrums of Antibodies against Aflatoxin.

Research about antibody specificity spectra was conducted to develop single-specific antibodies or broad-specific antibodies. Aflatoxins, as one class of high-toxicity mycotoxins, were selected as the...

Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.

The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by broadly neutralizing antibodies (bnAbs) 4E10 and 10E8. In this proof-of-concept study, we evaluated a novel multi-immunogen va...

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.

Durability of vaccine-elicited immune responses is one of the key determinants for vaccine success. Our aim is to develop a vaccination strategy against the human immunodeficiency virus type 1 (HIV-1)...

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and e...

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Antigenic drift and shift of influenza strains underscore the need for broadly protective influenza vaccines. One strategy is to design immunogens that elicit B cell responses against conserved epitop...

Clinical Trials [26 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.

Safety and Efficacy of G17DT Immunogen in the Treatment of Advanced Pancreatic Carcinoma

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymp

To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched pept...

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, With or Without a Candidate Vaccine

The purpose of this study is to determine the role of HIV-specific CD4 T cell responses and immune responses dependent upon these CD4 responses that develop when antiretroviral drugs are s...

Companies [7 Associated Companies listed on BioPortfolio]

ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agent...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunocon...

Industrial Research Limited - UK

IRL Biopharm is a highly skilled contract manufacturing business focused on developing and manufacturing novel secondary metabolites for our growing number of biotech and pharma clients around the glo...

Immunitor Corporation Co., Ltd

Immunitor Corporation Co., Ltd., is the first private biotech company formed in Thailand Technology developed by Immunitor allows to formulate any desired immunogen or antigen as an or...

Vical Incorporated

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applica...

More Information about "ImmunoGen" on BioPortfolio

We have published hundreds of ImmunoGen news stories on BioPortfolio along with dozens of ImmunoGen Clinical Trials and PubMed Articles about ImmunoGen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoGen Companies in our database. You can also find out about relevant ImmunoGen Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record